Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Go back to Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
(NASDAQ: TNYA) Delayed: 0.71 -0.02 (2.74%)
Previous Close $0.73    52 Week High
Open $0.72    52 Week Low
Day High $0.73    P/E N/A 
Day Low $0.70    EPS
Volume 759,895